StreetInsider.com News Articles

Form SCHEDULE 13G InMed Pharmaceuticals Filed by: ADAR1 Capital Management, LLC

Fri, 05 Jun 2026 16:44:00 -0400

si-local-file:///var/storage/secattach/20260605/26611836.html

Form SCHEDULE 13G InMed Pharmaceuticals Filed by: ADAR1 Capital Management, LLC

Fri, 05 Jun 2026 16:44:00 -0400

si-local-file:///var/storage/secattach/20260605/26611836.html

InMed Pharmaceuticals regains nasdaq listing compliance

Thu, 04 Jun 2026 17:02:09 -0400

InMed Pharmaceuticals Inc. (NASDAQ: INM) received notice from Nasdaq on June 3, 2026 that it has regained compliance with the exchange's minimum bid price requirement for continued listing.

The pharmaceutical company was previously notified by Nasdaq on March 27, 2026 that its common shares had failed to maintain a minimum bid price of $1.00 per share for 30 consecutive business days. Nasdaq determined that the closing bid price of InMed's common stock was at or above $1.00 per share for 10 consecutive business days from May 19, 2026 to June 2, 2026.

The company has now regained compliance with Nasdaq Listing Rule

InMed Pharmaceuticals Regains Compliance with Nasdaq Continued Listing Requirements

Thu, 04 Jun 2026 17:00:00 -0400

Vancouver, British Columbia--(Newsfile Corp. - June 4, 2026) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), today announce that it had received written notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") on June 3, 2026 informing the Company that it has regained compliance with Nasdaq Listing Rule 5550(a)(2), the minimum bid price requirement for continued listing on Nasdaq.

As previously disclosed, the Company was notified by Nasdaq on March 27, 2026 that its common shares had failed to maintain a minimum bid price of $1.00 per share for 30 consecutive business days. Nasdaq has now

InMed Pharmaceuticals Regains Compliance with Nasdaq Continued Listing Requirements

Thu, 04 Jun 2026 17:00:00 -0400

Form SCHEDULE 13G InMed Pharmaceuticals Filed by: Squadron Capital Management LLC

Wed, 27 May 2026 16:08:00 -0400

si-local-file:///var/storage/secattach/20260527/26557884.html

Form SCHEDULE 13G InMed Pharmaceuticals Filed by: Squadron Capital Management LLC

Wed, 27 May 2026 16:08:00 -0400

si-local-file:///var/storage/secattach/20260527/26557884.html

Form 4 InMed Pharmaceuticals For: May 19 Filed by: Schneeberger Daniel

Thu, 21 May 2026 17:08:00 -0400

si-local-file:///var/storage/secattach/20260521/26536751.html

Form 4 InMed Pharmaceuticals For: May 19 Filed by: Schneeberger Daniel

Thu, 21 May 2026 17:08:00 -0400

si-local-file:///var/storage/secattach/20260521/26536751.html

Form 3 InMed Pharmaceuticals For: May 19 Filed by: Schneeberger Daniel

Thu, 21 May 2026 16:51:00 -0400

si-local-file:///var/storage/secattach/20260521/26536342.html

Form 3 InMed Pharmaceuticals For: May 19 Filed by: Schneeberger Daniel

Thu, 21 May 2026 16:51:00 -0400

si-local-file:///var/storage/secattach/20260521/26536342.html

Form 425 InMed Pharmaceuticals Filed by: InMed Pharmaceuticals Inc.

Tue, 19 May 2026 10:34:00 -0400

si-local-file:///var/storage/secattach/20260519/26519233.html

Form 425 InMed Pharmaceuticals Filed by: InMed Pharmaceuticals Inc.

Tue, 19 May 2026 10:34:00 -0400

si-local-file:///var/storage/secattach/20260519/26519233.html

Form 8-K InMed Pharmaceuticals For: May 19

Tue, 19 May 2026 10:33:00 -0400

si-local-file:///var/storage/secattach/20260519/26519224.html

Form 8-K InMed Pharmaceuticals For: May 19

Tue, 19 May 2026 10:33:00 -0400

si-local-file:///var/storage/secattach/20260519/26519224.html

InMed to merge with Mentari in $290 million migraine therapy deal

Tue, 19 May 2026 08:06:08 -0400

InMed Pharmaceuticals Inc. (NASDAQ: INM) announced an all-stock merger agreement with privately-held Mentari Therapeutics Inc., a biotechnology company developing migraine prevention therapies. The combined entity will operate as Mentari Therapeutics and trade on the Nasdaq Capital Market under a new ticker symbol.

The transaction includes a concurrent $290 million private placement led by Fairmount, with participation from multiple investment firms including Commodore Capital, Deep Track Capital, Janus Henderson Investors, and Wellington Management. The funding is expected to support operations through 2028.

Mentari's pipeline includes two lead programs: MT-001, an anti-PACAP monoclonal antibody, and MT-002, an anti-CGRP and anti-PACAP bispecific antibody. First-in-human regulatory

InMed to merge with Mentari in $290 million migraine therapy deal

Tue, 19 May 2026 08:06:08 -0400

Mentari's pipeline includes two lead programs: MT-001, an anti-PACAP monoclonal antibody, and MT-002, an anti-CGRP and anti-PACAP bispecific antibody. First-in-human regulatory

InMed to merge with Mentari in $290 million migraine therapy deal

Tue, 19 May 2026 08:06:08 -0400

Mentari's pipeline includes two lead programs: MT-001, an anti-PACAP monoclonal antibody, and MT-002, an anti-CGRP and anti-PACAP bispecific antibody. First-in-human regulatory

InMed to merge with Mentari in $290 million migraine therapy deal

Tue, 19 May 2026 08:06:08 -0400

Mentari's pipeline includes two lead programs: MT-001, an anti-PACAP monoclonal antibody, and MT-002, an anti-CGRP and anti-PACAP bispecific antibody. First-in-human regulatory

InMed Pharmaceuticals & Mentari Therapeutics Announce Merger to Advance Migraine Prevention Therapies

Tue, 19 May 2026 08:00:00 -0400

Mentari's parallel lead programs target validated, complementary pathways with potential to address the two-thirds of patients who have a suboptimal response to anti-CGRP therapies

Concurrent oversubscribed US$290 million private placement of Mentari expected to fund company operations through 2028

First-in-human regulatory filings for MT-001 (anti-PACAP) and MT-002 (anti-CGRP x PACAP bispecific) expected mid-2026 and 1Q 2027, respectively

Conference call scheduled for May 19, 2026, at 8:30 AM EDT

VANCOUVER, BC and SAN FRANCISCO, May 19, 2026 /PRNewswire/ -- InMed Pharmaceuticals, Inc. (NASDAQ: INM) ("InMed" or the "Company") is

InMed Pharmaceuticals & Mentari Therapeutics Announce Merger to Advance Migraine Prevention Therapies

Tue, 19 May 2026 08:00:00 -0400

Mentari's parallel lead programs target validated, complementary pathways with potential to address the two-thirds of patients who have a suboptimal response to anti-CGRP therapies

Concurrent oversubscribed US$290 million private placement of Mentari expected to fund company operations through 2028

First-in-human regulatory filings for MT-001 (anti-PACAP) and MT-002 (anti-CGRP x PACAP bispecific) expected mid-2026 and 1Q 2027, respectively

Conference call scheduled for May 19, 2026, at 8:30 AM EDT

VANCOUVER, BC and SAN FRANCISCO, May 19, 2026 /PRNewswire/ -- InMed Pharmaceuticals, Inc. (NASDAQ: INM) ("InMed" or the "Company") is

InMed Pharmaceuticals & Mentari Therapeutics Announce Merger to Advance Migraine Prevention Therapies

Tue, 19 May 2026 08:00:00 -0400

Mentari's parallel lead programs target validated, complementary pathways with potential to address the two-thirds of patients who have a suboptimal response to anti-CGRP therapies

Concurrent oversubscribed US$290 million private placement of Mentari expected to fund company operations through 2028

First-in-human regulatory filings for MT-001 (anti-PACAP) and MT-002 (anti-CGRP x PACAP bispecific) expected mid-2026 and 1Q 2027, respectively

Conference call scheduled for May 19, 2026, at 8:30 AM EDT

VANCOUVER, BC and SAN FRANCISCO, May 19, 2026 /PRNewswire/ -- InMed Pharmaceuticals, Inc. (NASDAQ: INM) ("InMed" or the "Company") is

InMed Pharmaceuticals & Mentari Therapeutics Announce Merger to Advance Migraine Prevention Therapies

Tue, 19 May 2026 08:00:00 -0400

Mentari's parallel lead programs target validated, complementary pathways with potential to address the two-thirds of patients who have a suboptimal response to anti-CGRP therapies

Concurrent oversubscribed US$290 million private placement of Mentari expected to fund company operations through 2028

First-in-human regulatory filings for MT-001 (anti-PACAP) and MT-002 (anti-CGRP x PACAP bispecific) expected mid-2026 and 1Q 2027, respectively

Conference call scheduled for May 19, 2026, at 8:30 AM EDT

VANCOUVER, BC and SAN FRANCISCO, May 19, 2026 /PRNewswire/ -- InMed Pharmaceuticals, Inc. (NASDAQ: INM) ("InMed" or the "Company") is

InMed Pharmaceuticals & Mentari Therapeutics Announce Merger to Advance Migraine Prevention Therapies

Tue, 19 May 2026 08:00:00 -0400

Mentari's parallel lead programs target validated, complementary pathways with potential to address the two-thirds of patients who have a suboptimal response to anti-CGRP therapies

Concurrent oversubscribed US$290 million private placement of Mentari expected to fund company operations through 2028

First-in-human regulatory filings for MT-001 (anti-PACAP) and MT-002 (anti-CGRP x PACAP bispecific) expected mid-2026 and 1Q 2027, respectively

Conference call scheduled for May 19, 2026, at 8:30 AM EDT

VANCOUVER, BC and SAN FRANCISCO, May 19, 2026 /PRNewswire/ -- InMed Pharmaceuticals, Inc. (NASDAQ: INM) ("InMed" or the "Company") is

InMed Pharmaceuticals & Mentari Therapeutics Announce Merger to Advance Migraine Prevention Therapies

Tue, 19 May 2026 08:00:00 -0400

Mentari's parallel lead programs target validated, complementary pathways with potential to address the two-thirds of patients who have a suboptimal response to anti-CGRP therapies

Concurrent oversubscribed US$290 million private placement of Mentari expected to fund company operations through 2028

First-in-human regulatory filings for MT-001 (anti-PACAP) and MT-002 (anti-CGRP x PACAP bispecific) expected mid-2026 and 1Q 2027, respectively

Conference call scheduled for May 19, 2026, at 8:30 AM EDT

VANCOUVER, BC and SAN FRANCISCO, May 19, 2026 /PRNewswire/ -- InMed Pharmaceuticals, Inc. (NASDAQ: INM) ("InMed" or the "Company") is